Human epidermal growth factor (hEGF)

Human epidermal growth factor (hEGF)
Product Description

Good stability: conventional storage at ≤-20°C for one year results in little loss of activity, and after thawing, under aseptic conditions (2-8°C), there is little loss of activity for one month.Animal-free: produced by recombination, free of exogenous viral contamination, and no animal-derived raw materials are used in the production process.
Quality stability: batch production ensures continuous, stable batch production; no batch-to-batch differences and stable quality.
High purity: high specific activity; low residual host protein below the limit for biologics.
Complies with regulatory requirements: production equipment and environment comply with relevant regulations, and the production process fully complies with GMP guidelines.

Nanjing Cellnuo Biotechnology Co.,Ltd.

  • Country/Region:
    China
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Biopharmaceutical
Contract Manufacturer
Contract Research Organisation
Cosmetic Ingredients
Specifications
  • Details
    Product characteristics

    Product source: E.coli
    Product appearance: white or off-white powder
    Specific activity: ≥1*107units/mg
    Purity (HPLC): ≥94%
    Bacterial endotoxin: ≤10EU/mg
    Microbial limits: ≤300cfu/mg
  • Selling Points
    Price; Product Performance; Related products(For more detailed information, please contact us)

    FGF2, IGF-1, LR3, Transferrin, Noggin

  • Supplied from
    China

Nanjing Cellnuo Biotechnology Co.,Ltd.

  • Country/Region:
    China
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Biopharmaceutical
Contract Manufacturer
Contract Research Organisation
Cosmetic Ingredients

More Products from Nanjing Cellnuo Biotechnology Co.,Ltd. (7)

  • Degludec Insulin

    Product Degludec Insulin

    地谷胰岛素是一种长效人胰岛素类似物,通过重组DNA技术在大肠杆菌中表达,然后进行化学修饰。它在结构上与人胰岛素相当:非人胰岛素B30处的苏氨酸通过赖氨酸ε氨基上的L-γ-谷氨酸在B29处与十六烷脂肪酸侧链连接,可在体内可逆地与白蛋白结合,实现缓释。结合其多六聚体的缓释机制,其半衰期为≥36h,可实现每天一次的灵活给药。
  • Tirzepatide

    Product Tirzepatide

    Tilposide is a novel dual receptor agonist of glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic peptide (GIP), administered once a week. GLP-1 and GIP both belong to enterotropin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors ...
  • IGF LR3

    Product IGF LR3

    胰岛素基因家族成员长链LR3胰岛素样生长因子(LR3 lGF-1)在结构上与胰岛素前体蛋白相似,具有更好的生长促进作用,可促进细胞的分裂、迁移和分裂,与lGF-1相比,LR3 1GF-1具有更强的生物活性和更长的半衰期。在LR3 IGF-1蛋白中,精氨酸取代了iGF-1序列第三位的谷氨酸,N末端比lGF-1多13个氨基酸。与 lGF-1 相比,氨基酸透明度的差异导致 LR3 IGF-1 和 lGF-BP lGF 结合蛋白之间的亲和结合无和性较低,从而增加了 LR3 iGF-1 的半衰期和生物活性。在细胞培养过程中,LR3 lGF-1的生物活性与胰岛素相比显著增加。
  • IGF LR3

    Product IGF LR3

    胰岛素基因家族成员长链LR3胰岛素样生长因子(LR3 lGF-1)在结构上与胰岛素前体蛋白相似,具有更好的生长促进作用,可促进细胞的分裂、迁移和分裂,与lGF-1相比,LR3 1GF-1具有更强的生物活性和更长的半衰期。在LR3 IGF-1蛋白中,精氨酸取代了iGF-1序列第三位的谷氨酸,N末端比lGF-1多13个氨基酸。与 lGF-1 相比,氨基酸透明度的差异导致 LR3 IGF-1 和 lGF-BP lGF 结合蛋白之间的亲和结合无和性较低,从而增加了 LR3 iGF-1 的半衰期和生物活性。在细胞培养过程中,LR3 lGF-1的生物活性与胰岛素相比显著增加。
  • Insulin Icodec

    Product Insulin Icodec

    Insulin lcodec is a long-acting human insulin analogue expressed in Escherichia coli through recombinant DNA technologyand chemicaly modified.Comoared to human insulin in terms of structure,it has a threonine at the B30 position of unmanned insulin and introducesC20 fatty acids as side chains. This side of...
  • Recombinant Trypsin

    Product Recombinant Trypsin

    In compliance with pharmacopoeia standards: in compliance with relevant standards for recombinant proteases in pharmacopoeias.No animal origin: produced by recombination, free of exogenous viral contamination, and no animal-derived materials are used in the production process.
    Quality stability: mass pr...
  • Retatrutide API

    Product Retatrutide API

    Retatrutide is a polypeptide that can simultaneouslytarget GlP (glucose-dependent insulin-stimulating polypeptide),GLP-1(glucagon-like peptide-1), and glucagon recep-tor, and belongs to a "triple agonist". Administer the medicineonce a week.GLP-1, GlP and glucagon all belong to incretin, which is apolypept...

Nanjing Cellnuo Biotechnology Co.,Ltd. resources (3)